Eli Lilly
- Revenue$28.3 BFY, 2021
- Market Capitalization$309.4 B2022-06-24
OverviewSuggest Edit
Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. It offers diabetes and endocrinology, immunology, neuroscience, oncology, and other products. Its products are distributed through wholesalers that serve pharmacies, physicians, and other health care professionals and hospitals.
| Type | Public | |
| Founded | 1876 | |
| HQ | Indianapolis, IN, US | Map |
| Website | lilly.com | |
| Employee Ratings | ||
| Overall Culture | A- | More |
Recent NewsAll News
- Thinking about trading options or stock in Eli Lilly, Centene Corp, Snowflake, Apple, or Winnebago?
- AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
- Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche
- Eli Lilly And Parexel Talk About The ROI Of Practical AI
Key People/Management at Eli Lilly
David A. Ricks
Chairman and Chief Executive Officer
Anat Ashkenazi
Senior Vice President and Chief Financial Officer
Stephen F. Fry
Senior Vice President, Human Resources and Diversity
Johna L. Norton
Senior Vice President, Global Quality
Leigh Ann Pusey
Senior Vice President, Corporate Affairs and Communications
Daniel M. Skovronsky
Senior Vice President and Chief Scientific and Medical Officer
Eli Lilly Office Locations
Eli Lilly has offices in Indianapolis, Branchburg, Cambridge, New York and in 43 other locations
Indianapolis, IN, US (HQ)
893 Delaware St
Branchburg, NJ, US
33 Imclone Dr
Cambridge, MA, US
450 Kendall St
Indianapolis, IN, US
1223 W Morris St
Indianapolis, IN, US
1500 S Harding St
New York, NY, US
450 E 29th St 12th floor
Eli Lilly Financials and Metrics
Eli Lilly Revenue
Eli Lilly's revenue was reported to be $28.32 b in FY, 2021 which is a 15.4% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2022) | 7.8b |
Gross profit (Q1, 2022) | 5.7b |
Net income (Q1, 2022) | 1.9b |
Market capitalization (24-Jun-2022) | 309.4b |
Closing stock price (24-Jun-2022) | 325.6 |
Cash (30-Sept-2021) | 3.8b |
EV | 322.7b |
Eli Lilly's current market capitalization is $309.4 b.
Annual
Annual
Quarterly
| USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q4, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q4, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q4, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 123.5k | 5.2b | 5.9b | 6.0b | 6.5b | 6.1b | 6.6b | 5.9b | 4.1b | 4.3b | 5.3b | 4.0b | 3.9b | 3.8b | 4.4b | 3.9b | 3.8b | 3.2b | 3.1b | 3.3b | 3.2b | 2.3b | 3.2b | 3.5b | 2.6b | 3.1b | 3.7b | 3.1b | 6.8b | 9.0b | 2.0b | 2.3b | 1.6b | 1.7b | 2.4b | 3.6b | 3.0b | 3.2b | 3.8b |
Accounts Receivable | 3.2b | 3.1b | 3.3b | 3.5b | 3.7b | 3.8b | 3.5b | 3.6b | 3.4b | 3.2b | 3.3b | 3.3b | 3.4b | 3.6b | 3.4b | 3.0b | 3.2b | 3.1b | 3.1b | 3.3b | 3.4b | 3.6b | 3.9b | 3.8b | 4.0b | 4.3b | 4.4b | 4.5b | 4.8b | 4.9b | 4.2b | 4.6b | 4.4b | 5.1b | 4.8b | 4.9b | 5.6b | 5.8b | 5.9b |
Prepaid Expenses | 1.0b | 1.1b | 1.2b | 608.9m | 1.1b | 867.3m | 799.1m | 654.9m | 998.5m | 953.3m | 790.1m | 822.3m | 987.9m | 988.9m | 853.4m | 1.1b | 1.1b | 821.5m | 797.0m | 730.1m | 762.4m | 792.0m | 789.5m | 756.5m | 821.6m | 1.0b | 1.1b | 1.6b | 1.7b | 1.9b | 2.2b | 2.3b | 2.4b | 2.8b | 3.1b | 3.2b | 3.2b | 3.3b | 3.1b |
Inventories | 2.5b | 2.2b | 2.7b | 2.5b | 2.8b | 2.9b | 2.5b | 2.3b | 2.4b | 2.3b | 2.6b | 2.6b | 2.6b | 2.7b | 3.0b | 3.0b | 3.2b | 2.8b | 3.0b | 3.3b | 3.4b | 3.7b | 3.8b | 3.9b | 4.0b | 4.3b | 4.4b | 4.6b | 4.2b | 4.1b | 3.1b | 3.2b | 3.1b | 3.1b | 3.3b | 3.6b | 3.7b | 3.8b | 3.9b |
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.2b | 5.6b | 6.8b | 1.5b | 2.9b | 4.1b | 1.4b | 2.7b | 3.9b |
Depreciation and Amortization | 356.5m | 603.9m | 891.9m | 273.6m | 598.0m | 956.4m | 350.3m | 719.6m | 1.1b |
Cash From Operating Activities | 311.3m | 1.4b | 2.9b | 382.4m | 2.9b | 4.7b | 1.7b | 3.5b | 5.1b |
Purchases of PP&E | (203.7m) | (444.0m) | (707.4m) | (258.3m) | (540.1m) | (933.2m) | (300.3m) | (681.6m) | (1.0b) |
| USD | Q1, 2010 |
|---|---|
Debt/Equity | 0.6 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.6 x |
Eli Lilly Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Protomer Technologies | July 14, 2021 | $1 b |
| Prevail Therapeutics Inc. | January 01, 2021 | $880 m |
| Disarm Therapeutics | October 15, 2020 | $135 m |
| Disarm Therapeutics | October 15, 2020 | $135 m |
| Dermira | January 10, 2020 | $849.3 m |
| Dermira | January 10, 2020 | $1.1 b |
| Loxo Oncology | January 07, 2019 | $6.92 b |
| AurKa Pharma | May 15, 2018 | $575 m |
| ARMO BioSciences Inc | May 11, 2018 | $1.6 b |
| CoLucid Pharmaceuticals | January 18, 2017 | $960 m |
Eli Lilly Revenue Breakdown
Eli Lilly revenue breakdown by business segment: 44.2% from Diabetes, 19.1% from Oncology, 11.8% from Immunology, 5.6% from Neuroscience and 19.3% from Other
Eli Lilly revenue breakdown by geographic segment: 8.4% from Japan, 5.9% from China , 16.9% from Europe, 9.5% from Other foreign countries and 59.4% from United States
Human Capital Metrics
Eli Lilly Cybersecurity Score
Eli Lilly Environment, Social & Governance (ESG) Ratings
Eli Lilly Online and Social Media Presence
135.09k Twitter followers
Eli Lilly has 135.09k Twitter Followers. The number of followers has increased 0.5% month over month and increased 1.2% quarter over quarter
Eli Lilly's Trends
Twitter Engagement Stats for @lillypad
22.3k
Tweets
1.3k
Following
135.1k
Followers
39
Tweets last 30 days
3.6
Avg. likes per Tweet
61.5%
Tweets with engagement
Eli Lilly Company Culture
Overall Culture
A-
74/100
CEO Rating
A-
76/100
Compensation
A-
76/100
Diversity
C+
68/100
Eli Lilly News and Updates
June 23, 2022
Thinking about trading options or stock in Eli Lilly, Centene Corp, Snowflake, Apple, or Winnebago?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, CNC, SNOW, AAPL, and WGO. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
June 22, 2022
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada -
June 20, 2022
Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche
DUBLIN, June 20, 2022 /PRNewswire/ -- The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering. The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to...
June 09, 2022
Eli Lilly And Parexel Talk About The ROI Of Practical AI
Practical AI is the successful, measurable, business use of learning from data.
June 06, 2022
Stocks making the biggest moves midday: Sunrun, Eli Lilly, DiDi Global, CrowdStrike and more
These are the stocks posting the largest moves in midday trading.
May 31, 2022
Eli Lilly stock pulls back from record high after disclosing sales by largest shareholder
Shares of Eli Lilly & Co. fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nearly $64 million worth of its shares. In a Form 4 filing with the Securities and Exchange Commission, the co…
Eli Lilly Frequently Asked Questions
When was Eli Lilly founded?
Eli Lilly was founded in 1876.
Who are Eli Lilly key executives?
Eli Lilly's key executives are David A. Ricks, Anat Ashkenazi and Stephen F. Fry.
How many employees does Eli Lilly have?
Eli Lilly has 35,000 employees.
What is Eli Lilly revenue?
Latest Eli Lilly annual revenue is $28.3 b.
What is Eli Lilly revenue per employee?
Latest Eli Lilly revenue per employee is $809.1 k.
Who are Eli Lilly competitors?
Competitors of Eli Lilly include Shionogi, Boehringer Ingelheim and Sanofi.
Where is Eli Lilly headquarters?
Eli Lilly headquarters is located at 893 Delaware St, Indianapolis.
Where are Eli Lilly offices?
Eli Lilly has offices in Indianapolis, Branchburg, Cambridge, New York and in 43 other locations.
How many offices does Eli Lilly have?
Eli Lilly has 49 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies